Alexion aims to advance NMOSD treatment landscape with exceptional Ultomiris efficacy data at ECTRIMS 2022

Click here to view online. Add this email to your safelist.

12 October 2022

Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, 26 to 28 October 2022.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.